Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders

Cancer Treatment Reviews

Volumn 40, Issue 1, 2014, Pages 197-203

  Agustoni, Francesco ^a   Platania, Marco ^a   Vitali, Milena ^a   Zilembo, Nicoletta ^a   Haspinger, Eva ^a   Sinno, Valentina ^a   Gallucci, Rosaria ^a   De Braud, Filippo ^a   Garassino, Marina Chiara ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemotherapy; Non small cell lung cancer; Ocular toxicity; Ophthalmology; Target therapies

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; ARABINOSIDE; ARTIFICIAL TEAR; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CRIZOTINIB; CYTARABINE; DEXAMETHASONE; DICLOFENAC; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; METHOTREXATE; MILCICLIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NAVELBINE; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; SELUMETINIB; TEMOZOLOMIDE; TOPOTECAN; TRAMETINIB; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BLEPHARITIS; BLOOD EYE BARRIER; BLURRED VISION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER THERAPY; CEREBRAL BLINDNESS; CHORIORETINITIS; CONJUNCTIVITIS; CORNEA EDEMA; CORNEA EROSION; DACRYOCYSTORHINOSTOMY; DIPLOPIA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; EPIPHORA; EVOKED VISUAL RESPONSE; EYE PAIN; EYE TOXICITY; EYELID EDEMA; GLAUCOMA; HUMAN; KERATITIS; KERATOCONJUNCTIVITIS SICCA; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OPTIC NERVE DISEASE; OPTIC NEURITIS; OPTICAL TOMOGRAPHY; OVERALL SURVIVAL; PAPILLEDEMA; PERIORBITAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; RETINA ISCHEMIA; RETINA MACULA CYSTOID EDEMA; RETINA MACULOPATHY; RETINOPATHY; REVIEW; SCOTOMA; SKIN DEFECT; VISUAL DISORDER; VISUAL IMPAIRMENT; VITREORETINOPATHY;

CHEMOTHERAPY; NON-SMALL-CELL LUNG CANCER; OCULAR TOXICITY; OPHTHALMOLOGY; TARGET THERAPIES;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; EYE; EYE DISEASES; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS;

EID: 84887114679     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.05.005     Document Type: Review

References (74)

1. Schmid K.E., Kornek G.V., Scheithauer W., et al. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol 2006, 51(1):19-37.
2. Omoti A.E., Omoti C.E. Ocular toxicity of systemic anticancer chemotherapy. Pharm Pract 2006, 4(2):55-59.
3. al-Tweigeri T., Nabholtz J.M., Mackey J.R. Ocular toxicity and cancer chemotherapy. A review. Cancer 1996, 78(7):1359-1373.
4. Renouf D.J., Velasquez-Martin J.P., Simpson R., et al. Ocular toxicity of target therapies. J Clin Oncol 2012, 30(26):3277-3286. [10].
5. CTCAE4.02. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published: May 28, 2009 (v4.02: Sept. 15, 2009). US Department of Health and Human Services.
6. Azzoli C.G., Baker S., Temin S., et al. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
7. D'Addario G., Früh M., Reck M., et al. Non-small cell lung cancer: ESMO clinical reccomandations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl. 4):68-70.
8. Becher R., Schutt P., Oleska R. Peripheral neuropathy and ophtalmologic toxicity after treatment with cis-dichlorodiamminoplatinum. J. Cancer Res Clin Oncol 1980, 96:219-221.
9. Ostrow S., Hahn D., Wiernik P.H., et al. Ophthalmologic toxicity after cis-dichlorodiamminoplatinum(II) therapy. Cancer Treat Rep 1978, 62:1591-1594.
10. Walsh T.J., Clark A.W., Parhad I.M., et al. Neurotoxic effects of cisplatin therapy. Arch Neurol 1982, 39:719-720.
11. Berman I.J., Mann M.P. Seizures and transient cortical blindness associated with cisplatin therapy in a thirty year old man. Cancer 1980, 45:764-766.
12. Pippit C.H., Muss H.B., Homesley H.D., et al. Cisplatin-associated cortical blindness. Gynecol Oncol 1981, 12:253-255.
13. Caraceni A., Martini C., Spatti G., et al. Recovering optic neuritis during systemic cisplatin and carboplatin chemotherapy. Acta Neurol Scand 1997, 96:260-261.
14. Katz B.J., Ward J.H., Digre K.B., et al. Persistent severe visual and electroretinographic abnormalities after intravenous cisplatin therapy. J Neuroophthalmol 2003, 23(2):132-135.
15. Imperia P.S., Lazarus H.M., Lass J.H. Ocular complications of systemic cancer chemotherapy. Surv Ophthalmol 1989, 34:209-230.
16. Kwan A.S., Sahu A., Palaxes G. Retinal ischaemia with neovascularization in cisplatin related retinal toxicity. Am J Ophthalmol 2006, 141(1):196-197.
17. Lauer A.K., Wobig J.L., Shults W.T., et al. Severe ocular and orbital toxicity after intracarotid etoposide phosphate and carboplatin therapy. Am J Ophthalmol 1999, 127:230-233.
18. O'Brien M.E., Tonge K., Blake P., et al. Blindness associated with high dose carboplatin. Lancet 1992, 339:558.
19. Rankin E.M., Pitts J.K. Ophtalmic toxicity during carboplatin therapy. Ann Oncol 1993, 4:337-338.
20. Cloutier A.O. Ocular side effects of chemotherapy: nursing management. Oncol Nurs Forum 1992, 19(8):1251-1259.
21. Hazin R., Abuzetun J.Y., Daoud Y.J., et al. Ocular complications of cancer therapy: a primer for the ophtalmologist treating cancer patients. Curr Opin Ophthalmol 2009, 20(4):308-317.
22. Eguia B., Ruppert A.M., Fillon J., et al. Skin toxicities compromise prolonged pemetrexed treatment. J Thorac Oncol 2011, 6(12):2083-2092.
23. Matteucci P., Carlo-Stella C., Di Nicola M., et al. Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside. Haematologica 2006, 91(2):255-257.
24. Banach M.J., Williams G.A. Purtscher retinopathy and necrotizing vasculitis with gemcitabine therapy. Arch Ophtalmol 2000, 118:726-727.
25. Tran T.H., Desauw C., Rose C. Gemcitabine-induced retinopathy in a diabetic patient. Acta Ophtalmol 2008, 87(1):114-115.
26. Esmaeli B., Hidaji L., Adinin R.B., et al. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer 2003, 98:504-507.
27. Esmaeli B., Burnstine M.A., Ahmadi M.A. Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa. Ophthal Plast Reconstr Surg 2003, 19:305-308.
28. Skolnick C.A., Doughman D.J. Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere). Eye Contact Lens 2003, 29:134-135.
29. Capri G., Munzone E., Tarenzi E., et al. Optic nerve disturbance: new form of paclitaxel neurotoxicity. J Natl Cancer Inst 1994, 86:1099-1101.
30. 2. J Clin Oncol 1994, 12:1741-1742.
31. Kuznetcova T., Cech P., Herbort C.P. The mystery of angiographically silent macular oedema due to taxanes. Int Ophthalmol 2012, 32:299-304.
32. Georgakopoulos C.D., Makri O., Vasilakis P., et al. Angiographically silent cystoid macular oedema secondary to paclitaxel therapy. Clin Exp Optom 2012, 95:233-236.
33. Joshi M.M., Garretson B.R. Paclitaxel maculopaty (case report). Arch Ophtalmol 2007, 125:709-710.
34. Fabre-Guillevin E., Tchen N., Anibali-Charpiat M.F., et al. Taxane-induced glaucoma (case report). Lancet 1999, 354:1181-1182.
35. De Giorgi U., Acciarri R., Fiorentini G., et al. Glaucoma and paclitaxel (case report). Lancet 2000, 355:231.
36. Van Bockxmeer F.M., Martin C.M., Thompson D.E., et al. Taxol for the treatment of proliferative vitreoretinopathy. Invest Ophtalmol 1985, 26:1140-1147.
37. Yano S., Kondo K., Yamaguchi M., et al. Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 2003, 23:3639-3650.
38. Breider M.A. Irreversible inhibition of ErbB receptor family in rats results in epithelial atrophy and ulcerative dermatitis. Pharmacol Exp Ther 2000, 41:493.
39. Tullo A.B., Esmaeli B., Murray P.I., et al. Ocular findings in patients with solid tumors treated with epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa ZD1839) in Phase I and II clinical trials. Eye 2005, 19:729-738.
40. Iressa (gefitinib) tablets (prescribing information), AstraZeneca Pharmaceuticals, 2005.
41. Tarceva (erlotinib) tablets (prescribing information), OSI Pharmaceuticals, Inc. and San Francisco, calif: Genentech, Inc., 2005.
42. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005, 353(2):123-132.
43. Solca F, Schweifer N, Baum A, et al. BIBW 2992, an irreversible dual EGFR/her2 kinase inhibitor that show activity on L858R/T790M EGFR mutants. In: Proceedings of the AACR-NCI-EORTC international conference on molecular targets and cancer therapeutics, Philadelphia, PA, November 14-18, 2005, 118 (abstr A242).
44. Li D., Ambrogio L., Shimamura T., et al. BIBW 2992, an irreversible dual EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711.
45. Sos M.L., Rode H.B., Heynck S., et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 2010, 70:868-874.
46. Miller V.A., Hirsh V., Cadranel J., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomized trial. Lancet Oncol 2012, 13(5):528-538.
47. Yang J.C.H., Shih J.Y., Su W.C., et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012, 13:539-548.
48. Ranalingam S.S., Blackhall F., Krzakowski M., et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small cell lung cancer. J Clin Oncol 2012, 4(3):1-2. [Epub ahead of print].
49. Basti S. Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs 2007, 30(4):S10-S16.
50. Ciuleanu T., Stelmakh L., Cicenas S., et al. Erlotinib versus docetaxel or pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC) and poor prognosis: efficacy and safety results from the Phase III TITAN study. Lancet Oncol 2012, 13(3):300-308.
51. Rosell R., Carcenery E., Gervais R., et al. Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomized Phase 3 trial. Lancet Oncol 2012, 13(3):239-246.
52. Cappuzzo F., Ciuleanu T., Stelmakh L., et al. Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicentre, randomized, placebo-controlled, phase 3 study. Lancet Oncol 2010, 11(6):521-529.
53. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2004, 22(23):4811-4820.
54. Mok T.S., Wu Y.L., Au J.S., et al. Efficacy and safety of erlotinib in 1.242 East/South-east Asian patients with advanced non-small cell lung cancer. Thorac Oncol 2010, 5(10):1609-1615.
55. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet 2005, 366(9496):1527-1537.
56. Goss G., Ferry D., Wierzbicki R., et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naïve patients with advanced non-small cell lung cancer and poor performance status. J Clin Oncol 2009, 27(13):2253-2260.
57. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
58. Kim E.S., Hirsh V., Mok T.S., et al. Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomized Phase III trial. Lancet 2008, 372(9652):1809-1818.
59. Han J.Y., Park K., Kim S.W., et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012, 30(10):1122-1128.
60. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.
61. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open-label, randomized, phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
62. Ranson M., Hammond L.A., Ferry D., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002, 20:2240-2250.
63. Baselga J., Rischin D., Ranson M., et al. Phase I safety, pharmacokinetic and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002, 20:4292-4302.
64. Perez-Soler R., Chachoua A., Hammond L.A., et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 2004, 22(16):3238-3247.
65. Camidge DR, Bang Y, Kwak EL, et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC) [abstract no. 2501]. J Clin Oncol 2011; 29 Suppl. plus oral presentation at the 47th Meeting of the American Society of, Clinical Oncology; 2011 Jul 3-7; Chicago (IL).
66. Kim DW, Blackhall F, Soria JC, et al. A global phase 2 study including efficacy, safety, and patient-reported outcomes with crizotinib in patients with AL-positive non-small cell lung cancer [abstract no. 9084 plus oral presentation]. European Multidisciplinary Cancer Congress; 2011 Sep 23-27; Stockholm.
67. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med 2010, 363(18):1693-1703. [28].
68. Adjei A.A., Cohen R.B., Franklin W., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008, 26:2139-2146.
69. Banerji U., Camidge D.R., Verheul H.M., et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 2010, 16:1613-1623.
70. Hainsworth J.D., Cebotaru C.L., Kanarev V., et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 2010, 5:1630-1636.
71. Janne P.A., Shaw A.T., Rodriges Pereira J., Jeannin G., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small cell lung cancer: a randomised, multicentre, placebo-controlled, phase e study. Lancet Oncol 2013, 14:38-47.
72. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006, 24(11):1770-1783.
73. Benson C., Kaye S., Workman P., et al. Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br J Cancer 2005, 92(1):7-12.
74. Investigator Brochure for PHA-848125AC, Version 7. Nerviano Medical Sciences; 2011. Document no. CDKO-125a-IB7.